- Home
- CTNM
as 10-29-2025 9:36am EST
Stocks
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 328.1M | IPO Year: | 2024 |
| Target Price: | $22.20 | AVG Volume (30 days): | 95.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.35 - $20.24 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Contineum Therapeutics Inc. Class A Common Stock News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
MT Newswires
4 months ago
Contineum Therapeutics Progresses Enrollment for Phase 1b Trial of PIPE-791
Business Wire
4 months ago
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
MT Newswires
4 months ago
William Blair Initiates Coverage on Contineum Therapeutics With Outperform Rating
Simply Wall St.
5 months ago
Discover Real Brokerage And 2 Other Penny Stocks To Watch
Business Wire
5 months ago
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Business Wire
6 months ago
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Business Wire
6 months ago
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
Simply Wall St.
6 months ago
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate
Compare CTNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. Class A Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.